2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when the day was complete. However, things changed during the previous quarter.
Back in August, the embattled drugmaker wound up reporting organic growth from both of its core operating segments, Bausch & Lomb and Salix Pharmaceuticals, and it stuck by its full-year EBITDA forecast of $3.6 billion to $3.75 billion. While far from anything worth crowing over, it wasn't a bad report. That's the first time investors could say such a thing in about two years.
Source: Fool.com
Bausch Health Companies Inc. Stock
Currently there is a rather positive sentiment for Bausch Health Companies Inc. with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 7.26 € the target price of 16 € shows a potential of 120.39% for Bausch Health Companies Inc. which would more than double the current price.